Maxim Group Initiates Coverage on CERo Therapeutics (NASDAQ:CERO)
Analysts at Maxim Group began coverage on shares of CERo Therapeutics (NASDAQ:CERO – Get Free Report) in a note issued to investors on Monday, Marketbeat.com reports. The firm set a “buy” rating and a $3.00 price target on the stock. Maxim Group’s target price suggests a potential upside of 415.64% from the stock’s current price. […]
Analysts at Maxim Group began coverage on shares of CERo Therapeutics (NASDAQ:CERO – Get Free Report) in a note issued to investors on Monday, Marketbeat.com reports. The firm set a “buy” rating and a $3.00 price target on the stock. Maxim Group’s target price suggests a potential upside of 415.64% from the stock’s current price. […]
